The altered responses were reversed by treatment with Nrf2 agonists such as sulforaphane and compound 7, capable of rescuing ME1 expression, thus demonstrating that this enzyme can become a new therapeutic target against these bacterial infections through Keap1-Nrf2 PPI inhibitors (42, 46). This evidence concerns the gene KEAP1 and bacterial infectious disease.